# A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer

> **NCT06644170** · PHASE1 · COMPLETED · sponsor: **University of Washington** · enrollment: 15 (actual)

## Conditions studied

- Hematopoietic and Lymphatic System Neoplasm
- Metastatic Malignant Solid Neoplasm

## Interventions

- **BEHAVIORAL:** Behavioral Intervention
- **BEHAVIORAL:** Group Therapy
- **DRUG:** Psilocybin
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06644170
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-19
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06644170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06644170, "A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06644170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*